WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started a Phase I trial of the compound in the indication, and expects to initiate Phase II this year.

Although pirenzepine, a generic inhibitor of the muscarinic acetylcholine receptor M1 (CHRM1; HM1), is approved in Europe for treating ulcers, it has not been tested for neuropathy. WinSanTor claims it has freedom to operate for topical applications. ...